Literature DB >> 24353030

An internal radiation dosimetry computer program, IDAC 2.0, for estimation of patient doses from radiopharmaceuticals.

M Andersson1, L Johansson2, D Minarik3, S Mattsson3, S Leide-Svegborn3.   

Abstract

The internal dosimetry computer program internal dose assessment by computer (IDAC) for calculations of absorbed doses to organs and tissues as well as effective doses to patients from examinations with radiopharmaceuticals has been developed. The new version, IDAC2.0, incorporates the International Commission on Radiation Protection (ICRP)/ICRU computational adult male and female voxel phantoms and decay data from the ICRP publication 107. Instead of only 25 source and target regions, calculation can now be made with 63 source regions to 73 target regions. The major advantage of having the new phantom is that the calculations of the effective doses can be made with the latest tissue weighting factors of ICRP publication 103. IDAC2.0 uses the ICRP human alimentary tract (HAT) model for orally administrated activity and for excretion through the gastrointestinal tract and effective doses have been recalculated for radiopharmaceuticals that are orally administered. The results of the program are consistent with published data using the same specific absorption fractions and also compared with published data from the same computational phantoms but with segmentation of organs leading to another set of specific absorption fractions. The effective dose is recalculated for all the 34 radiopharmaceuticals that are administered orally and has been published by the ICRP. Using the new HAT model, new tissue weighting factors and the new adult computational voxel phantoms lead to an average effective dose of half of its earlier estimated value. The reduction mainly depends on electron transport simulations to walled organs and the transition from the stylised phantom with unrealistic interorgan distances to more realistic voxel phantoms.
© The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24353030     DOI: 10.1093/rpd/nct337

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  6 in total

1.  Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption.

Authors:  Sigrid Leide-Svegborn; Lars Ahlgren; Lennart Johansson; Sören Mattsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-06       Impact factor: 9.236

2.  IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms.

Authors:  Martin Andersson; Lennart Johansson; Keith Eckerman; Sören Mattsson
Journal:  EJNMMI Res       Date:  2017-11-03       Impact factor: 3.138

3.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Authors:  Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-26       Impact factor: 9.236

4.  Pediatric Nuclear Medicine Examinations and Subsequent Risk of Neoplasm: A Nationwide Population-Based Cohort Study.

Authors:  Mei-Kang Yuan; Shih-Chieh Chang; Mei-Chun Yuan; Ning-Ping Foo; Shan-Ho Chan; Shyh-Yau Wang; Cheng-Li Lin; Chung-Y Hsu; Chia-Hung Kao
Journal:  Front Med (Lausanne)       Date:  2021-12-20

5.  Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors.

Authors:  Martin Andersson; Lennart Johansson; David Minarik; Sigrid Leide-Svegborn; Sören Mattsson
Journal:  EJNMMI Phys       Date:  2014-09-29

6.  Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.

Authors:  Steffie M B Peters; Bastiaan M Privé; Maarten de Bakker; Frank de Lange; Walter Jentzen; Annemarie Eek; Constantijn H J Muselaers; Niven Mehra; J Alfred Witjes; Martin Gotthardt; James Nagarajah; Mark W Konijnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-04       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.